Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.

The roles and implications of RNA m6A modification in cancer

Open access
Deng, Xiaolan, Qing, Ying, Horne, David, Huang, Huilin, Chen, Jianjun·2023·Nature Reviews Clinical Oncology

Abstract

N6-Methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, has been extensively and increasingly studied over the past decade. Dysregulation of RNA m6A modification and its associated machinery, including writers, erasers and readers, is frequently observed in various cancer types, and the dysregulation profiles might serve as diagnostic, prognostic and/or predictive biomarkers. Dysregulated m6A modifiers have been shown to function as oncoproteins or tumour suppressors with essential roles in cancer initiation, progression, metastasis, metabolism, therapy resistance and immune evasion as well as in cancer stem cell self-renewal and the tumour microenvironment, highlighting the therapeutic potential of targeting the dysregulated m6A machinery for cancer treatment. In this Review, we discuss the mechanisms by which m6A modifiers determine the fate of target RNAs and thereby influence protein expression, molecular pathways and cell phenotypes. We also describe the state-of-the-art methodologies for mapping global m6A epitranscriptomes in cancer. We further summarize discoveries regarding the dysregulation of m6A modifiers and modifications in cancer, their pathological roles, and the underlying molecular mechanisms. Finally, we discuss m6A-related prognostic and predictive molecular biomarkers in cancer as well as the development of small-molecule inhibitors targeting oncogenic m6A modifiers and their activity in preclinical models. Dysregulation of N6-methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, is common in various cancer types. The authors of this Review provide an overview of the mechanisms of m6A-dependent RNA regulation, summarize current knowledge of their pathological effects and potential utility as biomarkers in cancer, and describe ongoing efforts to develop small-molecule inhibitors of oncogenic m6A modifiers. Epitranscriptomics relates to the post-transcriptional regulation of RNAs involving >170 chemical modifications, constituting one of several regulatory layers controlling gene expression. N6-Methyladenosine (m6A) is a major epitranscriptomic modification that contributes to the dynamic regulation of every biological process. m6A marks are reversibly added by writers and removed by erasers, and are recognized by readers; this machinery modulates RNA splicing, nuclear export, stability and translation to determine the fate of RNAs and thus ensure tight control over gene expression. Advanced global characterization and mapping techniques that provide information on locus-specific changes in m6A modification are key to a deeper understanding of the wide-ranging roles of m6A in the regulation of gene expression. Dysregulation of m6A modifiers (writers, erasers and readers) is common across cancer types and has essential roles in cancer initiation, progression, metastasis, metabolism, drug resistance and immune evasion as well as in the tumour microenvironment. Aberrant expression of m6A modifiers in cancer has been associated with a poor prognosis, therapy resistance and impaired antitumour immunity, and might therefore provide biomarkers with independent predictive value for use in diagnosis, prognostication and treatment selection. Preclinical data underscore the potential of small-molecule inhibitors of oncogenic m6A modifiers in the treatment of cancer, either alone or in combination with conventional chemotherapy or immunotherapies. Epitranscriptomics relates to the post-transcriptional regulation of RNAs involving >170 chemical modifications, constituting one of several regulatory layers controlling gene expression. N6-Methyladenosine (m6A) is a major epitranscriptomic modification that contributes to the dynamic regulation of every biological process. m6A marks are reversibly added by writers and removed by erasers, and are recognized by readers; this machinery modulates RNA splicing, nuclear export, stability and translation to determine the fate of RNAs and thus ensure tight control over gene expression. Advanced global characterization and mapping techniques that provide information on locus-specific changes in m6A modification are key to a deeper understanding of the wide-ranging roles of m6A in the regulation of gene expression. Dysregulation of m6A modifiers (writers, erasers and readers) is common across cancer types and has essential roles in cancer initiation, progression, metastasis, metabolism, drug resistance and immune evasion as well as in the tumour microenvironment. Aberrant expression of m6A modifiers in cancer has been associated with a poor prognosis, therapy resistance and impaired antitumour immunity, and might therefore provide biomarkers with independent predictive value for use in diagnosis, prognostication and treatment selection. Preclinical data underscore the potential of small-molecule inhibitors of oncogenic m6A modifiers in the treatment of cancer, either alone or in combination with conventional chemotherapy or immunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00774-x

Cites

256 of 256 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 256 references

Cited by

See all 364

Metadata

Authors
Deng, X., Qing, Y., Horne, D., Huang, H., & Chen, J.
Venue
Nature Reviews Clinical Oncology
Published
2023-05-23
Volume
20
Issue
8
Pages
507-526
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W4377820759
Cited by
364
References
256
FWCI
9.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The roles and implications of RNA m6A modification in cancer. https://app.cochat.ai/papers/10.1038/s41571-023-00774-x
The paper
Deng, X., Qing, Y., Horne, D., Huang, H., & Chen, J. (2023). The roles and implications of RNA m6A modification in cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-023-00774-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.